Edition:
United Kingdom

VBI Vaccines Inc (VBIV.OQ)

VBIV.OQ on NASDAQ Stock Exchange Capital Market

2.01USD
23 Oct 2018
Change (% chg)

$-0.11 (-5.19%)
Prev Close
$2.12
Open
$2.06
Day's High
$2.16
Day's Low
$1.86
Volume
49,150
Avg. Vol
87,708
52-wk High
$5.10
52-wk Low
$1.69

Latest Key Developments (Source: Significant Developments)

VBI Vaccines Appoints Christopher Mcnulty As CFO And Head Of Business Development
Wednesday, 15 Aug 2018 

Aug 15 (Reuters) - VBI Vaccines Inc ::VBI VACCINES APPOINTS CHRISTOPHER MCNULTY AS CHIEF FINANCIAL OFFICER AND HEAD OF BUSINESS DEVELOPMENT.SAYS CHRISTOPHER MCNULTY APPOINTED CFO.  Full Article

VBI Vaccines Q2 Loss Per Share $0.26
Thursday, 26 Jul 2018 

July 26 (Reuters) - VBI Vaccines Inc ::VBI VACCINES ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.26.Q2 REVENUE $200,000.Q2 REVENUE VIEW $679,000 -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.18 -- THOMSON REUTERS I/B/E/S.PIVOTAL PHASE 3 PROGRAM FOR SCI-B-VAC HEPATITIS B VACCINE CONTINUES TO ADVANCE TOWARDS TOPLINE DATA EXPECTED MID-YEAR 2019.VBI VACCINES - INITIAL DATA FROM PHASE 1/2A STUDY OF VBI-1901 FOR TREATMENT OF RECURRENT GLIOBLASTOMA EXPECTED H2 2018.ENDED Q2 WITH $41.1 MILLION IN CASH AND CASH EQUIVALENTS VERSUS $67.7 MILLION AS OF DEC 31, 2017.  Full Article

VBI Vaccines Files For Mixed Shelf Of Up To $150 Mln
Friday, 20 Jul 2018 

July 20 (Reuters) - VBI Vaccines Inc ::VBI VACCINES INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING.  Full Article

VBI Vaccines Announces Completion Of Enrollment In Protect Phase 3 Clinical Study For Sci-B-Vac Hepatitis B Vaccine
Thursday, 19 Apr 2018 

April 19 (Reuters) - VBI Vaccines Inc ::VBI VACCINES ANNOUNCES COMPLETION OF ENROLLMENT IN PROTECT PHASE 3 CLINICAL STUDY FOR SCI-B-VAC® HEPATITIS B VACCINE.VBI VACCINES INC - TOPLINE DATA FROM PROTECT STUDY ARE EXPECTED MID-YEAR 2019.  Full Article

Vbi Vaccines Announces Voluntary Delisting From The Toronto Stock Exchange
Monday, 12 Mar 2018 

March 12 (Reuters) - Vbi Vaccines Inc ::VBI VACCINES ANNOUNCES VOLUNTARY DELISTING FROM THE TORONTO STOCK EXCHANGE.VBI VACCINES - BOARD DECIDED TO VOLUNTARILY DELIST FROM TSX DUE TO VERY LIMITED TRADING ACTIVITY OF CO'S SHARES ON TSX.VBI VACCINES - LIMITED TRADING ACTIVITY OF CO'S SHARES ON TSX NO LONGER JUSTIFIES COSTS REQUIRED TO MAINTAIN DUAL-LISTING.VBI VACCINES - CO WILL CONTINUE TO HAVE "SIGNIFICANT" OPERATIONAL PRESENCE IN OTTAWA, CANADA.VBI VACCINES INC - SHARES WILL BE DELISTED FROM TSX, EFFECTIVE AT CLOSE OF TRADING ON MARCH 23.  Full Article

VBI Vaccines Announces First Patient Dosing In Phase 3 Clinical Program For Sci-B-Vac Hepatitis B Vaccine
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Vbi Vaccines Inc ::VBI VACCINES ANNOUNCES FIRST PATIENT DOSING IN PHASE 3 CLINICAL PROGRAM FOR SCI-B-VAC HEPATITIS B VACCINE.VBI VACCINES SAYS HEADLINE DATA FROM THE 15-MONTH PHASE 3 PROGRAM EXPECTED IN Q2 2019.VBI VACCINES SAYS 4,800 SUBJECTS EXPECTED TO ENROLL IN TRIAL ACROSS TWO PHASE 3 STUDIES, PROTECT AND CONSTANT.VBI VACCINES SAYS EXPECT TO SUBMIT MARKETING AUTHORIZATION APPLICATIONS FOR SCI-B-VAC TO U.S., EUROPEAN, CANADIAN AUTHORITIES IN 2019.  Full Article

VBI Vaccines announces full exercise of option to purchase additional shares, upsized registered direct offering for proceeds of $71.9 mln
Monday, 30 Oct 2017 

Oct 30 (Reuters) - VBI Vaccines Inc -:VBI Vaccines announces full exercise of underwriters’ option to purchase additional shares and upsized registered direct offering for aggregate proceeds of $71.9 million.VBI Vaccines Inc - ‍in addition, VBI's previously announced concurrent registered direct offering was upsized from US$20.8 million to US$22.8 million​.  Full Article

VBI vaccines prices concurrent public offering and registered direct offering
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - VBI Vaccines Inc :VBI Vaccines prices concurrent public offering and registered direct offering for aggregate proceeds of $63.5 million.Vbi Vaccines Inc - ‍pricing of offering at a price to public of US$3.05 per share​.  Full Article

VBI Vaccines announces proposed concurrent public offering
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - VBI Vaccines Inc ::VBI Vaccines announces proposed concurrent public offering and registered direct offering of common shares.VBI Vaccines- to use proceeds from offerings to fund pivotal phase III clinical program for SCI-B-VAC in U.S., Europe, Canada​.VBI Vaccines Inc - ‍ to also use proceeds from offerings for funding phase I/IIA clinical study of VBI-1901 for glioblastoma multiforme, among others.  Full Article

BRIEF-VBI Vaccines Announces Positive Final Phase 1 Study Results Of Preventative CMV Vaccine

* VBI VACCINES ANNOUNCES POSITIVE FINAL PHASE 1 STUDY RESULTS OF PREVENTATIVE CMV VACCINE